Proteostasis Therapeutics is a drug discovery company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Proteostasis Therapeutics went public in 2016 (NASDAQ: PTI). The company merged with Yumanity Therapeutics in 2020 and is no longer traded with the ticker symbol PTI.
Region: North America
NextWave Pharmaceuticals
NextWave Pharmaceuticals is a specialty pharmaceutical company seeking to create and promote differentiated products in the pediatric market. NextWave Pharmaceuticals was acquired by Pfizer.
Mersana Therapeutics
Mersana Therapeutics (NASDAQ: MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
LigoCyte
LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) developed linaclotide, a first-in-class therapy that received FDA approval for both irritable bowel syndrome and chronic constipation.
Ikano Therapeutics
Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures. Ikano was acquired by UCB.
FoldRx
FoldRx Pharmaceuticals focuses on creating disease modifying drug therapies for diseases of protein misfolding. FoldRx developed, tafamidis, the first-in-class therapy approved or TTR amyloidosis. FoldRx was acquired by Pfizer.
Dimension Therapeutics
Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics went public in 2015 (NASDAQ: DMTX). The company has since been acquired by Ultragenyx Pharmaceuticals and is no longer a publicly traded company.
Coherus Biosciences
Coherus Biosciences (NASDAQ: CHRS) is a biosimilar-focused, biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize high-quality biosimilar therapeutics worldwide.
CardioKine
CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.